…
Austco Healthcare Limited, together with its subsidiaries, engages in the business of development, manufacture, service, supply, and distribution of healthcare communications equipment and software in Australia, New Zealand, Asia, Europe, and North America. The company offers Tacera, an IP nurse call system; Medicom, a solution for nurse call system; Pulse Mobile which allows staff to manage nurse call functions on the go and trigger workflows remotely; clinical workflow that allows healthcare staff to communicate with ancillary departments, measure adherence to protocol, and control other systems; Built-in RTLS, a nurse call platform; enterprise reporting; and integration services. It is also involved in the marketing, sales, and installation of electronic healthcare communication systems; and development of software and manufacture of hardware relating to healthcare and electronic communications systems. The company was formerly known as Azure Healthcare Limited and changed its name to Austco Healthcare Limited in November 2020. Austco Healthcare Limited was founded in 1986 and is headquartered in Port Melbourne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Austco Healthcare Ltd supplies clinical communication, nurse-call systems and software to hospitals and aged-care providers in Australia and select overseas markets. Long-term growth may be supported by ageing populations, healthcare digitisation, regulatory focus on residential care and periodic technology upgrades, and the company appears positioned to capture recurring service and upgrade demand.
Major risks include dependence on aged-care and public procurement cycles, competition from larger vendors, execution risk on rollouts and exposure to supply-chain, currency and healthcare budget pressures that investors should monitor.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | 11.58M | 8.06M | 5.65M | 1.81M | 2.63M |
| Minority interest | 0.00M | - | - | - | - |
| Net income | 9.01M | 5.93M | 7.08M | 2.26M | 2.33M |
| Selling general administrative | 26.16M | 1.46M | 1.46M | 14.42M | 11.98M |
| Selling and marketing expenses | - | 25.62M | 19.14M | -12.74M | - |
| Gross profit | 20.96M | 42.37M | 30.67M | 6.68M | 18.85M |
| Reconciled depreciation | 3.97M | 2.87M | 2.31M | 1.72M | 1.38M |
| Ebit | 10.82M | 10.59M | 5.80M | 1.80M | 2.14M |
| Ebitda | 14.80M | 11.10M | 8.11M | 3.52M | 3.52M |
| Depreciation and amortization | 3.97M | 0.51M | 2.31M | 1.72M | 1.38M |
| Operating income | 10.82M | 10.87M | 5.79M | 1.80M | 2.14M |
| Other operating expenses | 83.42M | 70.53M | 52.37M | 40.17M | 33.74M |
| Interest expense | 0.39M | 0.23M | 0.15M | 0.07M | 0.05M |
| Tax provision | 2.58M | 2.12M | -1.43M | -0.44M | 0.30M |
| Interest income | 0.17M | 0.32M | 0.06M | 0.04M | 0.02M |
| Net interest income | -0.21M | 0.10M | -0.09M | -0.03M | -0.03M |
| Income tax expense | 2.58M | 2.12M | -1.43M | -0.44M | 0.30M |
| Total revenue | 94.24M | 81.41M | 58.15M | 41.98M | 35.88M |
| Total operating expenses | 10.14M | 31.50M | 24.89M | 4.88M | 16.71M |
| Cost of revenue | 73.28M | 39.03M | 27.48M | 35.29M | 17.03M |
| Total other income expense net | 0.76M | -2.82M | -0.14M | 0.01M | 0.52M |
| Net income from continuing ops | 9.00M | 5.93M | 7.08M | 2.26M | 2.33M |
| Net income applicable to common shares | - | 5.93M | 7.08M | 2.26M | 2.33M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 88.50M | 91.07M | 68.72M | 37.81M | 34.03M |
| Intangible assets | 6.84M | 6.79M | - | 5.46M | 4.68M |
| Other current assets | 2.39M | 4.18M | 1.81M | 0.22M | 1.54M |
| Total liab | 26.38M | 39.34M | 24.34M | 12.81M | 10.94M |
| Total stockholder equity | 62.12M | 51.73M | 44.38M | 25.00M | 23.09M |
| Deferred long term liab | - | - | - | 5.46M | 4.68M |
| Other current liab | 6.57M | 9.39M | 4.49M | 2.57M | 3.50M |
| Common stock | 58.48M | - | 54.47M | 42.19M | 41.72M |
| Capital stock | 58.48M | 54.89M | - | 42.19M | 41.72M |
| Retained earnings | 4.57M | -4.44M | -10.63M | -17.86M | -18.90M |
| Other liab | - | - | - | 0.05M | 0.04M |
| Good will | 21.35M | 21.35M | 14.49M | - | - |
| Other assets | - | - | 0.00M | 7.18M | 5.60M |
| Cash | 16.28M | 14.48M | 13.56M | 4.67M | 7.63M |
| Cash and equivalents | - | - | - | 4.67M | 7.63M |
| Total current liabilities | 23.54M | 33.15M | 17.06M | 12.64M | 10.49M |
| Current deferred revenue | 3.80M | - | 2.67M | - | 1.44M |
| Net debt | -12.33M | - | -11.78M | - | -6.65M |
| Short term debt | 1.24M | - | 0.57M | 0.02M | 0.56M |
| Short long term debt | 0.14M | 0.16M | - | 0.02M | 0.05M |
| Short long term debt total | 3.95M | - | 1.78M | - | 0.98M |
| Other stockholder equity | 0.00M | - | - | 0.67M | 0.27M |
| Property plant equipment | - | - | - | 0.85M | 1.09M |
| Total current assets | 50.31M | 51.55M | 40.57M | 29.79M | 27.34M |
| Net tangible assets | - | - | - | 25.00M | 23.09M |
| Net receivables | 20.35M | 21.82M | 14.53M | 12.83M | 7.62M |
| Inventory | 11.30M | 9.28M | 10.67M | 10.83M | 9.21M |
| Accounts payable | 11.94M | 10.97M | 9.32M | 8.34M | 6.74M |
| Accumulated other comprehensive income | -0.93M | - | 0.54M | - | 0.27M |
| Non currrent assets other | - | - | 6.26M | - | - |
| Non current assets total | 38.18M | 39.51M | 28.15M | 8.02M | 6.70M |
| Capital lease obligations | 3.81M | 3.72M | - | 0.50M | 0.93M |
| Long term debt total | - | - | - | 0.12M | 0.42M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -12.32M | -11.06M | -1.57M | -1.63M |
| Change to liabilities | - | - | - | 1.79M | 3.13M |
| Total cashflows from investing activities | -8.82M | -12.32M | -11.06M | -1.57M | -1.63M |
| Net borrowings | - | - | -0.01M | -0.69M | -0.60M |
| Total cash from financing activities | -1.43M | -0.40M | 8.84M | -1.58M | -0.31M |
| Change to operating activities | - | - | - | 0.80M | -0.10M |
| Net income | 9.01M | 5.93M | 7.08M | 2.26M | 2.33M |
| Change in cash | 1.79M | 0.93M | 8.88M | -2.96M | -0.14M |
| Begin period cash flow | 14.48M | 13.56M | 4.67M | 7.63M | 7.77M |
| End period cash flow | 16.28M | 14.48M | 13.56M | 4.67M | 7.63M |
| Total cash from operating activities | 12.51M | 13.42M | 11.35M | 0.32M | 1.94M |
| Issuance of capital stock | - | 0.42M | 9.58M | - | 0.28M |
| Depreciation | 3.97M | 2.87M | 2.31M | 1.72M | 1.38M |
| Other cashflows from investing activities | -6.04M | -2.77M | -2.27M | - | - |
| Dividends paid | - | - | 0.00M | -0.90M | 0.90M |
| Change to inventory | -2.02M | 1.39M | 0.16M | -1.61M | -3.53M |
| Change to account receivables | 3.51M | -8.58M | -0.91M | -4.60M | -1.57M |
| Sale purchase of stock | -0.02M | 0.42M | 9.58M | 0.00M | 0.28M |
| Other cashflows from financing activities | -1.43M | - | -0.73M | -0.66M | -0.57M |
| Change to netincome | - | - | - | 0.21M | 0.44M |
| Capital expenditures | 0.79M | 2.76M | 3.90M | 1.57M | 1.63M |
| Change in working capital | -2.23M | -3.49M | 1.62M | -3.87M | -2.04M |
| Stock based compensation | - | 0.31M | 0.19M | 0.15M | 0.19M |
| Other non cash items | 1.76M | 7.80M | 0.15M | 7.26M | 0.25M |
| Free cash flow | 11.72M | 10.66M | 7.45M | -1.25M | 0.32M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AHC Austco Healthcare Ltd |
-0.01 3.64% |
0.27 | 13.75 | 16.31 | 1.09 | 1.63 | 0.94 | 5.71 |
| RMD Resmed Inc |
0.14 0.40% |
34.75 | 21.77 | 19.57 | 8.49 | 5.53 | 5.50 | 14.10 |
| FPH Fisher & Paykel Healthcare Corporation Ltd |
0.31 0.80% |
39.20 | 55.56 | 48.54 | 9.91 | 12.92 | 11.78 | 33.96 |
| ANN Ansell Ltd |
0.14 0.31% |
45.66 | 21.27 | 22.73 | 2.99 | 2.16 | 2.24 | 12.03 |
| NAN Nanosonics Ltd |
-0.06 2.03% |
2.89 | 49.17 | 78.12 | 4.33 | 4.02 | 3.64 | 24.30 |
Austco Healthcare Limited, together with its subsidiaries, engages in the business of development, manufacture, service, supply, and distribution of healthcare communications equipment and software in Australia, New Zealand, Asia, Europe, and North America. The company offers Tacera, an IP nurse call system; Medicom, a solution for nurse call system; Pulse Mobile which allows staff to manage nurse call functions on the go and trigger workflows remotely; clinical workflow that allows healthcare staff to communicate with ancillary departments, measure adherence to protocol, and control other systems; Built-in RTLS, a nurse call platform; enterprise reporting; and integration services. It is also involved in the marketing, sales, and installation of electronic healthcare communication systems; and development of software and manufacture of hardware relating to healthcare and electronic communications systems. The company was formerly known as Azure Healthcare Limited and changed its name to Austco Healthcare Limited in November 2020. Austco Healthcare Limited was founded in 1986 and is headquartered in Port Melbourne, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Clayton Astles | CEO, MD & Exec. Director | NA |
| Mr. Brendan James Maher | CFO & Company Sec. | 1968 |
| Mr. Andrew Hall | Chief Commercial Officer | NA |
| Mr. Michael Read | Gen. Mang. of Australasia | NA |
| Mr. Clayton Astles | CEO, MD & Executive Director | NA |
| Mr. Brendan James Maher | CFO & Company Secretary | 1968 |
| Mr. Clayton Astles | CEO, MD & Executive Director | NA |
| Mr. Brendan James Maher | CFO & Company Secretary | 1968 |
| Mr. Clayton Astles | CEO, MD & Executive Director | NA |
| Mr. Brendan James Maher | CFO & Company Secretary | 1968 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.